tirzepatide kidney stones GLP‑1 medications are becoming more common for diabetes management and weight loss, and many patients wonder how they may affect health. Kyle Wood, M.D., MBA, shares insights on current research on Can GLP‑1 medications increase kidney

We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use

Conclusions Our findings do not support an increased risk of intestinal obstruction in T2DM patients prescribed GLP-1 RAs compared to other anti-diabetic medications.

Because when used correctly for the right reasons, this drug can genuinely help

Lose weight faster with Lipostat+ injections

Novo Nordisk, Eli Lilly, Pfizer, Amgen and Roche are the major companies operating in this market.

Since the results of a Phase 2b clinical trial were published in 2017, the Parkinsons community has focused a lot of attention on a class of diabetes drugs called Glucagon-like peptide-1 (or GLP-1)agonists. Last year, the results of another Phase 2 GLP-1 agonist study in Parkinsons provided further encouraging data